open access

Vol 93, No 7 (2022)
Research paper
Published online: 2021-06-24
Get Citation

Serum neudesin levels in patients with polycystic ovary syndrome

Hamiyet Yilmaz Yasar1, Mustafa Demirpence1, Ayfer Colak2, Merve Zeytinli2, Erdem Yasar3, Ali Taylan4
·
Pubmed: 34263912
·
Ginekol Pol 2022;93(7):525-530.
Affiliations
  1. Department of Endocrinology, Tepecik Research and Training Hospital, Izmir, Turkey
  2. Department of Biochemistry, Tepecik Research and Training Hospital, Izmir, Turkey
  3. Department of Anesthesiology and Algology, Katip Celebi University, Ataturk Research and Training Hospital, Izmir, Turkey
  4. Department of Rheumatology, Tepecik Research and Training Hospital, Izmir, Turkey

open access

Vol 93, No 7 (2022)
ORIGINAL PAPERS Gynecology
Published online: 2021-06-24

Abstract

Objectives: We aimed to investigate serum neudesin levels that has neural, metabolic functions in patients with polycystic ovary syndrome (PCOS).

Material and methods: The study included 180 women (age range, 18–44 years) with a diagnosis of PCOS and a control group that included 100 healthy females (age range, 18–46 years). Body mass index (BMI), waist circumference, Ferriman-Gallwey score, was evaluated and plasma glucose, lipid profile, estradiol, progesterone, total testosterone, prolactin, insulin, dehydroepiandrosterone sulfate (DHEA-S), FSH, LH, free T3, free T4, thyroid stymulating hormone (TSH), anti-thyroperoxidase (anti-TPO) antibody and neudesin levels were evaluated in all participants.

Results: BMI and waist circumference were similar between two groups. Ferriman-Gallwey score was significantly higher in the patient group. Fasting blood glucose, HbA1C, lipid parameters except triglyceride levels, free T3, free T4, TSH, anti-TPO were similar between the two groups. Triglyceride, insulin and HOMA values were significantly higher in PCOS patients. While follicle-stimulating hormone (FSH), estradiol, progesterone, prolactin and DHEAS levels were similar, LH was significantly higher in patients with PCOS. Serum neudesin level was significantly lower in PCOS patients with respect to controls (p = 0.015). Neudesin was positively correlated with insulin (r = 0.224, p = 0.037), and progesterone (r = 0.716, p = 0.001). Multiple regression analysis revealed that neudesin correlated with only progesterone (beta = 0.308, p = 0.001).

Conclusions: Due to the association of decreased levels of neudesin with PCOS and correlation of neudesin with progesterone, neudesin may be related with one of patophysiologic pathways of PCOS. Still, it is not certain that decreased neudesin is involved in the pathogenesis of PCOS or is the result of the disorder.

Abstract

Objectives: We aimed to investigate serum neudesin levels that has neural, metabolic functions in patients with polycystic ovary syndrome (PCOS).

Material and methods: The study included 180 women (age range, 18–44 years) with a diagnosis of PCOS and a control group that included 100 healthy females (age range, 18–46 years). Body mass index (BMI), waist circumference, Ferriman-Gallwey score, was evaluated and plasma glucose, lipid profile, estradiol, progesterone, total testosterone, prolactin, insulin, dehydroepiandrosterone sulfate (DHEA-S), FSH, LH, free T3, free T4, thyroid stymulating hormone (TSH), anti-thyroperoxidase (anti-TPO) antibody and neudesin levels were evaluated in all participants.

Results: BMI and waist circumference were similar between two groups. Ferriman-Gallwey score was significantly higher in the patient group. Fasting blood glucose, HbA1C, lipid parameters except triglyceride levels, free T3, free T4, TSH, anti-TPO were similar between the two groups. Triglyceride, insulin and HOMA values were significantly higher in PCOS patients. While follicle-stimulating hormone (FSH), estradiol, progesterone, prolactin and DHEAS levels were similar, LH was significantly higher in patients with PCOS. Serum neudesin level was significantly lower in PCOS patients with respect to controls (p = 0.015). Neudesin was positively correlated with insulin (r = 0.224, p = 0.037), and progesterone (r = 0.716, p = 0.001). Multiple regression analysis revealed that neudesin correlated with only progesterone (beta = 0.308, p = 0.001).

Conclusions: Due to the association of decreased levels of neudesin with PCOS and correlation of neudesin with progesterone, neudesin may be related with one of patophysiologic pathways of PCOS. Still, it is not certain that decreased neudesin is involved in the pathogenesis of PCOS or is the result of the disorder.

Get Citation

Keywords

neudesin; membrabe-associated progesteron receptors; pathogenesis of polycystic ovary syndrome

About this article
Title

Serum neudesin levels in patients with polycystic ovary syndrome

Journal

Ginekologia Polska

Issue

Vol 93, No 7 (2022)

Article type

Research paper

Pages

525-530

Published online

2021-06-24

Page views

5267

Article views/downloads

1255

DOI

10.5603/GP.a2021.0139

Pubmed

34263912

Bibliographic record

Ginekol Pol 2022;93(7):525-530.

Keywords

neudesin
membrabe-associated progesteron receptors
pathogenesis of polycystic ovary syndrome

Authors

Hamiyet Yilmaz Yasar
Mustafa Demirpence
Ayfer Colak
Merve Zeytinli
Erdem Yasar
Ali Taylan

References (30)
  1. Azziz R, Carmina E, Dewailly D, et al. Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006; 91(11): 4237–4245.
  2. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed). 1986; 293(6543): 355–359.
  3. Bednarska S, Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: what's new? Adv Clin Exp Med. 2017; 26(2): 359–367.
  4. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997; 18(6): 774–800.
  5. Çakır E, Çakal E, Özbek M, et al. The correlation between polycystic ovary syndrome and cardiovascular disease risk. Turk Jem. 2013; 17: 33–37.
  6. Bozkırlı E, Bakıner O, Ertörer E, et al. Insulin resistance in non-obese polycystic ovary syndrome subjects and relation with family history of diabetes mellitus. Turk Jem. 2015; 19(2): 55–59.
  7. Wołczyński S, Zgliczyński W. Abnormalities of the menstrual cycle. In: Zgliczyński W. ed. Large interna — Endocrynology. Medical Tribune Poland, Warszawa 2012: 561–567.
  8. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81(1): 19–25.
  9. Ohta H, Kimura I, Konishi M, et al. Neudesin as a unique secreted protein with multi-functional roles in neural functions, energy metabolism, and tumorigenesis. Front Mol Biosci. 2015; 2: 24.
  10. Petersen SL, Intlekofer KA, Moura-Conlon PJ, et al. Novel progesterone receptors: neural localization and possible functions. Front Neurosci. 2013; 7: 164.
  11. Bozkaya G, Fenercioglu O, Demir İ, et al. Neudesin: a neuropeptide hormone decreased in subjects with polycystic ovary syndrome. Gynecol Endocrinol. 2020; 36(10): 849–853.
  12. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961; 21: 1440–1447.
  13. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7): 412–419.
  14. Burt Solorzano CM, Beller JP, Abshire MY, et al. Neuroendocrine dysfunction in polycystic ovary syndrome. Steroids. 2012; 77(4): 332–337.
  15. Waldstreicher J, Santoro NF, Hall JE, et al. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab. 1988; 66(1): 165–172.
  16. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016; 37(5): 467–520.
  17. Wu S, Divall S, Nwaopara A, et al. Obesity-induced infertility and hyperandrogenism are corrected by deletion of the insulin receptor in the ovarian theca cell. Diabetes. 2014; 63(4): 1270–1282.
  18. Endoh A, Kristiansen SB, Casson PR, et al. The zona reticularis is the site of biosynthesis of dehydroepiandrosterone and dehydroepiandrosterone sulfate in the adult human adrenal cortex resulting from its low expression of 3 beta-hydroxysteroid dehydrogenase. J Clin Endocrinol Metab. 1996; 81(10): 3558–3565.
  19. Ryu C, Klein K, Zanger U. Membrane associated progesterone receptors: promiscuous proteins with pleiotropic functions — focus on interactions with cytochromes P450. Frontiers Pharmacol. 2017; 8: 159.
  20. Hughes AL, Powell DW, Bard M, et al. Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. Cell Metab. 2007; 5(2): 143–149.
  21. Peluso JJ, Romak J, Liu X. Progesterone receptor membrane component-1 (PGRMC1) is the mediator of progesterone's antiapoptotic action in spontaneously immortalized granulosa cells as revealed by PGRMC1 small interfering ribonucleic acid treatment and functional analysis of PGRMC1 mutations. Endocrinology. 2008; 149(2): 534–543.
  22. Peluso JJ, Liu X, Gawkowska A, et al. Progesterone activates a progesterone receptor membrane component 1-dependent mechanism that promotes human granulosa/luteal cell survival but not progesterone secretion. J Clin Endocrinol Metab. 2009; 94(7): 2644–2649.
  23. Krebs CJ, Jarvis ED, Chan J, et al. A membrane-associated progesterone-binding protein, 25-Dx, is regulated by progesterone in brain regions involved in female reproductive behaviors. Proc Natl Acad Sci U S A. 2000; 97(23): 12816–12821.
  24. Bashour NM, Wray S. Progesterone directly and rapidly inhibits GnRH neuronal activity via progesterone receptor membrane component 1. Endocrinology. 2012; 153(9): 4457–4469.
  25. Kimura I, Nakayama Y, Yamauchi H, et al. Neurotrophic activity of neudesin, a novel extracellular heme-binding protein, is dependent on the binding of heme to its cytochrome b5-like heme/steroid-binding domain. J Biol Chem. 2008; 283(7): 4323–4331.
  26. Byerly MS, Swanson RD, Semsarzadeh NN, et al. Identification of hypothalamic neuron-derived neurotrophic factor as a novel factor modulating appetite. Am J Physiol Regul Integr Comp Physiol. 2013; 304(12): R1085–R1095.
  27. Ohta H, Konishi M, Kobayashi Y, et al. Deletion of the neurotrophic factor neudesin prevents diet-induced obesity by increased sympathetic activity. Sci Rep. 2015; 5: 10049.
  28. Kimura I, Nakayama Y, Zhao Y, et al. Neurotrophic effects of neudesin in the central nervous system. Front Neurosci. 2013; 7: 111.
  29. Zheng Q, Li Y, Zhang D, et al. ANP promotes proliferation and inhibits apoptosis of ovarian granulosa cells by NPRA/PGRMC1/EGFR complex and improves ovary functions of PCOS rats. Cell Death Dis. 2017; 8(10): e3145.
  30. Schuster J, Karlsson T, Karlström PO, et al. Down-regulation of progesterone receptor membrane component 1 (PGRMC1) in peripheral nucleated blood cells associated with premature ovarian failure (POF) and polycystic ovary syndrome (PCOS). Reprod Biol Endocrinol. 2010; 8: 58.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl